Search by Medical Condition

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Clinical Trials for Colonic Neoplasms

• Evaluation the of Role of Vitamin D Supplement on Tumor Response, Inflammation and Apoptosis in Patients With Stage II or III Colorectal Cancer Receiving Chemotherapy.
• Cemiplimab With Fianlimab for Resectable Non-Metastatic Colon Cancer
• Patient Preference for Subcutaneous vs. Intravenous Immune Therapy
• A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
• A Study to Investigate the Safety and Preliminary Efficacy of GSK5460025 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
• A Study to Characterize Encorafenib Plus Cetuximab as Rechallenge Treatment for BRAF V600E-mutant Metastatic Colorectal Cancer Patients After Previous Therapy With BRAF Inhibitors-based Combinations
• QL1706 Plus XELOX as Neoadjuvant Therapy for MSS/pMMR Clinical Stage III Colon Cancer
• Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
• Immunotherapy (Toripalimab) for Reducing Recurrence Risk After Surgery for Mismatch Repair Deficient Stage IIB, IIC, or III Colon Cancer
• Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer
• A Study of PHN-012 in Patients With Advanced Solid Tumors
• Low-dose Trifluridine/Tipiracil With Bevacizumab in mCRC
• A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
• A Phase II Platform Study to Evaluate Treatment With Cemiplimab Monotherapy or Cemiplimab Plus Fianlimab or Other Novel Combinations in Patients With Colorectal Cancer With Minimal Residual Disease Following Definitive Surgery and Chemotherapy (
• A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
• A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With Metastatic Colorectal Cancer (mCRC)
• Phase Clinical Trial of Cadonilimab Combined With Anti-angiogenic Agents in Metastatic dMMR/MSI-H CRC
• Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients
• A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
• Erector Spinae Plane Block as Analgesia in Patients for Colectomy
• Radiotherapy + Systemic Therapy as Conversion Therapy for pMMR/MSS T4M0 Colon CancerNeo-Color
• Effect of Lidocaine or Dexamethasone on Cancer Immune Response- the PILDI Study
• Study of Treatment With Intensified Omeprazole Treatment to Prevent High Output Stoma 1
• Pre-Operative Treatment in REseCTable COlon CanceR
• MFOLFOXIRI Plus PD-1 Inhibitor Vs MFOLFOX6 As Neoadjuvant Therapy for Locally Advanced Colon Cancer
• Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
• The Use of Indocyanine Green Near-infrared Fluorescence for Bowel Perfusion Quantitative Assessment in Order to Prevent Anastomotic Leakage in Colorectal Surgery
• Impact of Vascular Endothelial Growth Factor Gene Polymorphisms on Bevacizumab Efficacy in a Sample of Iraqi Patients With Metastatic Colorectal Cancer
• A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations
• Phase II Study of Neoadjuvant Dostarlimab in Patients With Untreated T3-4N0-2 or Stage III pMMR/MSS Resectable Colon Cancer
• Neoadjuvant CAPOX Plus Ivonescimab Versus CAPOX for Locally Advanced Colon Cancer
• Phytocannabinoids for Reducing Chronic Chemotherapy-Induced Peripheral Neuropathy in Breast and Colon Cancer Survivors
• Target-specific immunoPET Imaging of Digestive System Carcinoma
• A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors
• HDAC Inhibitor Combination with Chemoimmunotherapy in the Neoadjuvant Treatment of PMMR Locally Advanced Colon Cancer
• A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
• A Study of Perioperative QL1706 in Participants With Untreated dMMR/MSI-H Resectable Colon Cancer
• Brodalumab in the Treatment of Immune-Related Adverse Events
• CGA Guided Ultrafractionated RT and First-line Systemic Treatment in Elderly or Frail Patients with MCRC
• CGA Guided Ultrafractionated RT and Systemic Treatment in Elderly or Frail Patients with Inoperable Localized CRC
• Neoadjuvant Pembrolizumab With a Watch-and-wait Strategy for dMMR/MSI-H Localized Colon Cancer: PREMICES Study.
• Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC
• Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
• First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
• CtDNA-guided Selection of Adjuvant Chemotherapy Regimens for Elderly Colon Cancer Patients After Surgery: a Single-center, Randomized, Controlled Study
• A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
• Node-Sparing Short-Course Radiation with CAPOX and Sintilimab for MSS Locally Advanced Colon Cancer: a Randomized, Prospective, Multicenter Study
• Immune Checkpoint Inhibitors for Organ Preservation in Non-metastatic dMMR/MSI-H Gastric or Colon Cancers
• Botensilimab, Balstilimab and Regorafenib or Botensilimab and Balstilimab for the Treatment of Advanced or Metastatic Microsatellite Stable Colorectal Cancer
• Modified FOLFOXIRI Plus Target Therapy as a First Line Treatment for Advanced Colorectal Cancer a Prospective Phase Two Study
• A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer
• Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer
• First-Line Treatment Induced With mFOLFOX6 and HLX04 Regimen, Following Combined With Serplulimab in MSS Initially Unresectable Metastatic Colorectal Cancer
• The Sagittarius Trial
• A Study of PHN-010 in Patients With Advanced Solid Tumors
• A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
• De-scalation or swItch of Treatment According to Circulating tuMOr DNA Variation After 2 Cycles of Doublet Chemotherapy Plus Targeted Agent in Metastatic Unresectable Colorectal Cancer
• The Effect of Probiotics ATG-F4 in Cancer Patients
• Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
• KRAS-Targeted Vaccine Combined With Balstilimab and Botensilimab for Patients With Stage IV MMR-p Colorectal Cancer and Pancreatic Ductal Cancer
• Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon Cancer
• Topical Tretinoin Prophylaxis for Anti-EGFR Induced Skin Toxicity in Metastatic Colorectal Cancer
• PD1 Antibody Combined With mFOLFOX6 Neoadjuvant Therapy for Advanced Resectable Metastatic Colon Cancer
• tislelizUMaB in canceR Patients With molEcuLar residuaL Disease
• Personalising and Refining Neo-adjuvant Chemotherapy in Locally Advanced but Resecable Colon Cancer in the Elderly of 70 Years Old or More
• Comparison of Intravenous Lidocaine vs Ketamine in Colorectal Surgery
• Evaluation of Metastatic Disease and Oncological Treatment in Patients With Colon Cancer Using Zebra Fish Avatars
• Study of Fruquintinib Combined With Tegafur Gimeracil Oteracil in Patients With Metastatic Colorectal Cancer
• CtDNA in Adjuvant Chemotherapy of Stage III Colon Cancer (REVISE Trial)
• Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors
• A Phase II Clinical Study of the Efficacy and Safety of Tislelizumab Combined With Fruquintinib and Chidamide in the Treatment of Unresectable or Advanced Microsatellite Stabilized (MSS/pMMR) Colorectal Cancer With Liver Metastases
• Neoadjuvant Immunotherapy for T4 dMMR Colon Cancer
• Localized Treatment Versus Palliative Chemotherapy in CRC Patients With 10 or More CRLM
• Neoadjuvant Tislelizumab With Chemotherapy for the Treatment of MSS Colon Cancer
• Neoadjuvant Chemotherapy for Obstructive Colon cancER First Treated by cOlostomy
• Envafolimab Monotherapy or Envafolimab + CAPEOX as Neoadjuvant Therapy for Locally Advanced Colorectal Cancer
• Safety and Feasibility of Immuno-OCT
• A Study to Investigate Ompenaclid Combined With FOLFIRI Plus Bevacizumab in Advanced/Metastatic Colorectal Cancer
• The Phoenix Trial: Phase II Trial of Cemiplimab for the Non-operative Management of Localized dMMR Colon Cancer
• A Clinical Trial Evaluating the Efficacy and Safety of IBI310 in Combination With Sintilimab, for Neoadjuvant Treatment of MSI-H/dMMR Resectable Colon Cancer
• XKDCT080 in GCC-positive Recurrent or Refractory Solid Tumors With Single Center, Single Arm, and Dose Escalation
• Neoadjuvant Chemoimmunotherapy for Resectable Non-Metastatic Proficient Mismatch Repair (PMMR) Colon Cancer
• Study of Perioperative Dostarlimab in Participants With Untreated T4N0 or Stage III dMMR/MSI-H Resectable Colon Cancer
• A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors
• Neoadjuvant Immunotherapy in Locally Advanced Colon Cancers
• Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases
• Short-course Radiotherapy Combined With Chemotherapy and Pd-1 Inhibitor for Locally Advanced Colon Cancer(TORCH-C)
• Testing the Use of BRAF-Targeted Therapy After Surgery and Usual Chemotherapy for BRAF-Mutated Colon Cancer
• Xian-Lian-Jie-Du Optimization Decoction as an Adjuvant Treatment for Prevention of Recurrence of Colon Cancer
• Response to Immunotherapy in MMR-deficient Localized Colon Cancer
• Comparison of Oral Lactulose Versus Polyethylene Glycol for Bowel Preparation in Low-risk Patients
• Propofol With Clonidine and Ketamine Throughout Colon Cancer Surgery
• Platform Study of Circulating Tumor DNA Directed Adjuvant Chemotherapy in Colon Cancer
• Study of an Individualized Vaccine Targeting Neoantigens in Combination With Immune Checkpoint Blockade for Patients With Colon Cancer
• Repurposing the Antipsychotic Drug Chlorpromazine as Adjuvant Therapeutic Agent for Resected Stage III Colon Cancer
• Tranexamic Acid During Colonic Endoscopic Resection Procedures
• To Determine the Efficacy and Safety of Envafolimab Combined With XELOX for Locally Advanced Colon Cancer
• Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
• Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer
• Intravenous Iron Infusion on Chemotherapy-induced Anemia
• Microbiotic Product (NBT-NM108) to Reduce Chemotherapy-Induced Diarrhea
• Argipressin's Influence on Blood Loss and Inflammatory Response During Hepatic Resection
• Clinical Trial on HIPEC With Mitomycin C in Colon Cancer Peritoneal Metastases (GECOP-MMC)
• Single Arm Study of Neoadjuvant Dostarlimab in Stage II and III Deficient Mismatch Repair Colon Cancers
• A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.
• Camrelizumab Combined With Neoadjuvant Chemotherapy After Stent Placement for Left-Sided Obstructive Colonic Cancer
• Neoadjuvant FOLFOXIRI Versus Immediate Surgery for Stage II and III Colon Cancers
• Adjuvant FOLFOXIRI for High-risk Stage III Colon Cancer
• A Single Arm Phase II Study to Evaluate Treatment With Gevokizumab in Patients With Stage II/III Colon Cancer Who Are ctDNA-positive After Curative Surgery and Adjuvant Chemotherapy
• Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
• Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors
• A Dose Escalation Study of SHP2 Inhibitor in Patients With Solid Tumors Harboring KRAS of EGFR Mutations
• Low-dose Neuroleptanalgesia for Postoperative Delirium in Elderly Patients
• Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients
• A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
• Abdominal Drainage vs Postoperative Antibiotico-prophylaxis vs Control in Laparoscopic Right Hemicolectomy With Intracorporeal Anastomosis for Right Colon Cancer
• Adagrasib in Combination With BI 1701963 in Patients With Cancer (KRYSTAL 14)
• Immunotherapy Versus Chemotherapy as Adjuvant Therapy for Colon Cancer With MSI-H or POLE/ POLD1 Mutations
• Mesalamine for Colorectal Cancer Prevention Program in Lynch Syndrome
• Outcome of Neoadjuvant Chemotherapy for Obstructive Colon Cancer
• FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases
• Effect of Low-dose Interferon-alfa2a on Peri-operative Immune Suppression
• A Prospective Study Utilizing Circulating Cell Free DNA (cfDNA) Use in the Detection of RAS Mutations in Patients With Advanced Colorectal Cancer.
• 18F-FMAU PET/CT and MRI for the Detection of Brain Tumors in Patients With Brain Cancer or Brain Metastases
• Phase I/II Trial of the Combination of Bintrafusp Alfa (M7824), Entinostat and NHS-IL12 (M9241) in Patients With Advanced Cancer
• Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Patients With Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial
• Preoperative i.v. Iron Substitution in Patients With Colon Cancer
• Neoadjuvant Therapy for Locally Advanced Right-sided Colon Cancer
• LY3214996 and Cetuximab Alone or in Combination With Abemaciclib for the Treatment of Unresectable or Metastatic Colorectal Cancer
• SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial
• Immunoscore as Decision Guidance for Adjuvant Chemotherapy in Colon Cancer
• The Value of Palliative Primary Tumor Resection in Metastatic Colon Cancer
• Study of ASN004 in Patients With Advanced Solid Tumors
• Triplezumab Combined With CAPEOX Regimen in Neoadjuvant Therapy for Locally Advanced Colon Cancer
• Regorafenib, Ipilimumab and Nivolumab for the Treatment of Chemotherapy Resistant Microsatellite Stable Metastatic Colorectal Cancer
• Lymph Node Ratio and Kras Mutation in R Colon Cancer
• A Study of Efficacy and Safety of Fruquintinib (HMPL-013) in Patients With Metastatic Colorectal Cancer
• Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: The VAPOR-C Trial
• Preoperative Endoscopic Treatment With Fosfomycin and Metronidazole in Patients With Right-sided Colon Cancer and Colon Adenoma (MEFO-trial)
• Adjuvant Chemotherapy in High Risk Stage II Colon Cancer
• TAS-102 and Oxaliplatin for the Treatment of Refractory Stage IV Colon Cancer
• Post-surgical Liquid Biopsy-guided Treatment of Stage III and High-risk Stage II Colon Cancer Patients: the PEGASUS Trial
• Anesthesia and Cancer Study: Colon Cancer
• Pembrolizumab in Early Stage Colon Cancer
• Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for the Treatment of Resectable, Refractory, or Recurrent Rhabdomyosarcoma in Pediatric Patients, T.O.A.S.T. I.T. Study
• The Clinical Study of Adjuvant Chemotherapy on Intestinal and Urethral Flora in Patients With Gastric and Colon Cancer
• Dasatinib in Preventing Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer Receiving FOLFOX and Bevacizumab
• Preoperative Nivolumab in Patients With Locally Advanced Colon Cancer (T3 or T4): a Window-of-opportunity Study
• CIRCULATING TUMOR DNA BASED DECISION FOR ADJUVANT TREATMENT IN COLON CANCER STAGE II
• TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study
• Immunotherapy With Y90-RadioEmbolization for Metastatic Colorectal Cancer
• Circulating Tumour DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II Evaluation
• Circulating Tumor DNA Testing in Predicting Treatment for Patients With Stage IIA Colon Cancer After Surgery
• Phase 1b Study to Evaluate ATP128, VSV-GP128 and BI 754091, in Patients With Stage IV Colorectal Cancer
• Encorafenib, Binimetinib, and Nivolumab in Treating Patients With Microsatellite Stable BRAF V600E Metastatic Colorectal Cancer
• The Effectiveness of High-dose Intravenous Vitamin c With Very Low Carbohydrate Diet for Terminal Colon Cancer Patients
• Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
• A Trial of CXD101 in Combination With Nivolumab in Patients With Metastatic Microsatellite-Stable Colorectal Cancer
• Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer
• The Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer
• Niraparib and Panitumumab in Patients With Advanced or Metastatic Colorectal Cancer
• Binimetinib and Palbociclib or TAS-102 in Treating Patients With KRAS and NRAS Mutant Metastatic or Unresectable Colorectal Cancer
• Preoperative High Protein vs Immunodiet in Surgical Cancer Patients
• Neoadjuvant Chemoradiotherapy Versus Neoadjuvant Chemotherapy For Unresectable Locally Advanced Colon Cancer
• Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable dMMR/MSI-H Colorectal Cancer
• Foxy-5 as Neo-Adjuvant Therapy in Subjects With Wnt-5a Low Colon Cancer
• Pembrolizumab After Chemotherapy in Treating Patients With Colorectal Cancer That Has Spread to the Liver and Who Are Undergoing Liver Surgery
• Circulating Cell-Free Tumor DNA Testing in Guiding Treatment for Patients With Advanced or Metastatic Colorectal Cancer
• Avelumab Plus 5-FU Based Chemotherapy as Adjuvant Treatment for Stage 3 MSI-High or POLE Mutant Colon Cancer
• Effect of Adding Simethicone to Split-dose Polyethylene Glycol for Bowel Preparation in a Screening Colonoscopy Setting
• Identification and Treatment Of Micrometastatic Disease in Stage III Colon Cancer
• Nivolumab and Metformin in Patients With Treatment Refractory MSS Colorectal Cancer
• Targeted Polymeric Nanoparticles Loaded With Cetuximab and Decorated With Somatostatin Analogue to Colon Cancer
• Sym004 Versus TAS-102 in Patients With mCRC
• Herbal Treatment to Improve Chemotherapy Delivery
• Regorafenib and Nivolumab in Mismatch Repair (MMR) Refractory Colorectal Cancer
• Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer
• Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
• OMega-3 Fatty Acid for the Immune Modulation of Colorectal Cancer
• Regorafenib and Pembrolizumab in Treating Participants With Advanced or Metastatic Colorectal Cancer
• A Study of Bevacizumab, Infusional Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (A-FOLFOXIRI) Compared With Bevacizumab, Infusional Fluorouracil, Leucovorin, and Irinotecan/Oxaliplatin (A-FOLFIRI/FOLFOX) as First-line Treatment for Metastat
• Interest of the Nefopam and PCA Morphine Combination for Postoperative Analgesia in Patients Undergoing Colon Surgery
• A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
• Peripheral Parenteral Nutrition vs Conventional Fluid in Colorectal Resection in ERAS
• Chemotherapy and/or Metastasectomy in Treating Patients With Metastatic Colorectal Adenocarcinoma With Lung Metastases
• Savolitinib in Treating Patients With MET Amplified Metastatic or Unresectable Colorectal Cancer
• Guadecitabine and Nivolumab in Treating Refractory Metastatic Colorectal Cancer
• Sym004 Versus Futuximab or Modotuximab in Patients With mCRC
• The Effects of Mechnikov Probiotics on Symptom and Surgical Outcome
• Cetuximab Therapy for Third Line Rechallenge in Metastatic Colorectal Cancer
• Combined Immunotherapy and Radiosurgery for Metastatic Colorectal Cancer
• Vinorelbine in Advanced BRAF-like Colon Cancer
• Mechanical Bowel Preparation and Oral Antibiotics Before Colon Cancer Surgery
• ASPIRIN Trial Belgium
• A Study of TAK-164 in Participants With Advanced Gastrointestinal (GI) Cancer Expressing Guanylyl Cyclase C (GCC)
• Palbociclib and Cetuximab in Metastatic Colorectal Cancer
• PhII Trial Panitumumab, Nivolumab, Ipilimumab in Kras/Nras/BRAF Wild-type MSS Refractory mCRC
• EPA for Metastasis Trial 2
• Study of Durvalumab (MEDI4736) (Anti-PD-L1) and Trametinib (MEKi) in MSS Metastatic Colon Cancer
• Neoadjuvant FOLFOX Chemotherapy for Patients With Locally Advanced Colon Cancer
• A Study of ASN007 in Patients With Advanced Solid Tumors
• Ginseng in Decreasing Cancer-Related Fatigue After Treatment in Cancer Survivors
• Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
• Pembrolizumab, Capecitabine, and Bevacizumab in Treating Patients With Microsatellite Stable Colorectal Cancer That Is Locally Advanced, Metastatic, or Cannot Be Removed by Surgery
• METIMMOX: Colorectal Cancer METastasis - Shaping Anti-tumor IMMunity by OXaliplatin
• S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery
• EMI-137 in Laparoscopic Colonic Resections
• Metformin Treatment for Colon Cancer
• Trametinib and Trifluridine and Tipiracil Hydrochloride in Treating Patients With Colon or Rectal Cancer That is Advanced, Metastatic, or Cannot Be Removed by Surgery
• Adjuvant Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) in Resected High Risk Colon Cancer Patients
• LEAn Body Mass Normalization of OXaliplatin Based Chemotherapy
• Impact of Adjuvant Chemotherapy in Patients With Colon Cancer
• Efficacy of Postoperative Adjuvant Chemotherapy for Stage II Colon Cancer With High Risk Factors(EPAC1)
• Ultrasound Guided Transversus Abdominis Plane(TAP) Block in Intensive Care Unit
• Reduced Dose of Prophylactic Dexamethasone for Elderly Patients Receiving Moderate Emetogenic Chemotherapy
• A Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer
• A "Window Trial" on Boswellia for Breast Cancer Primary Tumors
• Study of QRH-882260 Heptapeptide Application in the Colon
• Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors
• Nivolumab, Ipilimumab and COX2-inhibition in Early Stage Colon Cancer: an Unbiased Approach for Signals of Sensitivity
• TVB 2640 for Resectable Colon Cancer Other Resectable Cancers; a Window Trial.
• Adjuvant Chemotherapy In Elderly With Colon Cancer Stage III
• Proactive Management of Endoperitoneal Spread in Colonic Cancer
• IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting
• PK/PD Investigation of Calciumfolinat in Blood, Tumor and Adjacent Mucosa in Patient With Colon Cancer
• Multimodal Narcotic Limited Perioperative Pain Control With Colorectal Surgery
• Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk
• Evaluation of New Histoprognostic Criteria in a Retrospective Study of Colon Cancers Operated at Amiens University Hospital
• Patient Satisfaction With Propofol for Out Patient Colonoscopy
• Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
• Perioperative Chemotherapy VS Postoperative Chemotherapy for the Treatment of Colon Cancer With Resectable Liver Metastasis
• Chemopreventive Effects of Epigallocatechin Gallate (EGCG) in Colorectal Cancer (CRC) Patients
• A Phase II Study of Tegafur-Uracil as Maintenance Chemotherapy in Patients With Stage II of Colon Cancer
• Neoadjuvant Chemotherapy for the Treatment of Resectable Locally Advanced Colon Cancer
• TAS-OX for Refractory Metastatic Colon Cancer
• Maintenance Tegafur-uracil Versus Observation Following Adjuvant Oxaliplatin-based Regimen in Patients With Stage III Colon Cancer After Radical Resection
• Pembrolizumab + Poly-ICLC in MRP Colon Cancer
• Exploratory Study of ART-123 for the Prevention of Cancer Treatment Related Symptoms in Patients With Postoperative Stage II / III Colon Cancer
• Laparoscopic Surgery VS Laparoscopic Surgery + Neoadjuvant Chemotherapy for T4 Tumor of the Colon Cancer
• Predictive Biomarkers of Biological Activity and Efficacy of Nilotinib on ZAK Target in Non-metastatic Colon Cancer
• Curcumin in Combination With 5FU for Colon Cancer
• A Study of Niclosamide in Patients With Resectable Colon Cancer
• Imatinib as Pre-operative Anti-Colon Cancer Targeted Therapy
• A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon Cancer
• Aquamin and Prevention of Colon Cancer
• L-Menthol Infusion as a Novel Technique During Colonoscopy
• A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum
• Pan FGFR Kinase Inhibitor BGJ398 and Combination Chemotherapy in Treating Patients With Untreated Metastatic Pancreatic Cancer
• FOLFOX or CAPOX Perioperative Chemotherapy Versus Postoperative Chemotherapy for Locally Advanced Colon Cancer (OPTICAL)
• Assessment of the Anesthetic Effect on the Activity of Immune Cell in Patient With Colon Cancer
• Assessing How the Viscosity of Submucosal Gel Injections Helps With Endoscopic Mucosal Resections
• Synergistic Anti-tumor Effect of ChangTai Keli for Colon Cancer Patients
• Finding the Best Dose of Aspirin to Prevent Lynch Syndrome Cancers
• Safety of Xeloda in Solid Tumours
• Adjuvant Aspirin Treatment for Colon Cancer Patients
• RhGM-CSF as Adjuvant Immunotherapy in Treating Stage III Colon Cancer
• Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
• A Multi-center Randomized Controlled Trial of Intraportal Chemotherapy Combined With Adjuvant Chemotherapy (mFOLFOX6) for Stage II and III Colon Cancer
• Nintedanib and Capecitabine in Treating Patients With Refractory Metastatic Colorectal Cancer
• A Study of rSIFN-co in Subjects With Advanced Solid Tumors
• Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy
• Different Bowel Preparations in CT Colonography: is Diet Necessary? A Randomized Controlled Trial
• Colectomy in Patients With Asymptomatic and Unresectable Stage IV Colon Cancer
• Influence of Epidural Analgesia on Natural Killer Cell (NK) Activity After Colonic Cancer Surgery
• Effects of Different Types of Perioperative Analgesia on Minimal Residual Disease Development After Colon Cancer Surgery
• A Trial of Aspirin on Recurrence and Survival in Colon Cancer Patients
• A Phase Ⅱ Study of XELOX Chemotherapy With or Without Surgery of Primary Lesion for Colon Cancer Patients
• Cytokine-induced Killer Cell Immunotherapy for Surgical Resected Stage III Colorectal Cancer Patients After Chemotherapy
• Observational Study to Evaluate the Use of Targeted Therapies in Metastatic Colorectal Cancer
• Ziv-Aflibercept Followed by Ziv-Aflibercept, Fluorouracil, and Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer
• CPI-613 and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer That Cannot Be Removed by Surgery
• Effect of Omega-3 Fatty Acids on the Perioperative Immune Response and Erythrocyte Function
• Adjuvant HIPEC in High Risk Colon Cancer
• Vitamin D in Patients With Stage I-III Colon Cancer or Resectable Colon Cancer Liver Metastases
• Genotype-Directed Study Of Irinotecan Dosing In FOLFIRI + BevacizumabTreated Metastatic Colorectal Cancer
• Glucagon Use in Colonoscopies
• An Investigational Immuno-therapy Study of Nivolumab, and Nivolumab in Combination With Other Anti-cancer Drugs, in Colon Cancer That Has Come Back or Has Spread
• MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer
• A Study Evaluating Veliparib as a Single Agent or in Combination With Chemotherapy in Subjects With Solid Tumors
• Resection vs no Resection of the Primary in Colorectal Cancer With Unresectable Metastases
• A Study to Evaluate the Effects of Veliparib on Heart Rhythms in Patients With Solid Tumors
• Genistein in Treatment of Metastatic Colorectal Cancer
• Cancer and Anesthesia: Survival After Radical Surgery - a Comparison Between Propofol or Sevoflurane Anesthesia
• SGI-110 in Combination With an Allogeneic Colon Cancer Cell Vaccine (GVAX) and Cyclophosphamide (CY) in Metastatic Colorectal Cancer (mCRC)
• Short-Infusion Ziv-aflibercept in Treating Patients With Metastatic Colorectal Cancer Receiving Combination Chemotherapy
• Irinotecan and Alisertib in Treating Patients With Advanced Solid Tumors or Colorectal Cancer
• Neoadjuvant Chemotherapy Versus Standard Treatment in Patients With Locally Advanced Colon Cancer
• Lymphoseek® as Lymphoid Tissue Targeting Agents in Colon Cancer(CNC)
• Pre-operative Decitabine in Colon Cancer: a Proof of Principle Study
• Standard and High Dose Irinotecan Based on UGT1A1 Genotype for First-line Treatment of Locally Advanced Colon Cancer
• Panitumumab and Chemotherapy in Patients With Advanced Colorectal Cancer After Prior Therapy With Bevacizumab
• 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
• Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Locally Advanced and Cannot Be Removed by Surgery
• Trial on Mechanical Bowel Preparation in Laparoscopic Colorectal Surgery
• Physiological Effects of Altering Cancer-related Inflammation
• A Dose Finding Study of Eribulin Mesylate and Cetuximab For Patients With Advanced Head and Neck and Colon Cancer
• A Trial of Maintenance ADAPT Therapy With Capecitabine and Celecoxib in Patients With Metastatic Colorectal Cancer
• Pharmacodynamic and Clinical Evaluation of Dose and Taste-optimised Low Volume PEG-based Bowel Cleansing Solutions Using the Split-dosing Intake Regimen in Healthy Subjects and in Subjects Undergoing Screening Colonoscopy
• PK/PD Investigation of Modufolin (Arfolitixorin) in Plasma, Tumor and Adjacent Mucosa Adjacent Mucosa in Patients With Colon Cancer
• An Observational Study of Xeloda (Capecitabine) in Patients With Metastatic Colorectal Cancer, Colon Cancer in the Adjuvant Setting, Advanced Gastric Cancer or Breast Cancer
• Genotype-guided Dosing of mFOLFIRINOX Chemotherapy in Patients With Previously Untreated Advanced Gastrointestinal Malignancies
• Cetuximab and Everolimus in Treating Patients With Metastatic or Recurrent Colon Cancer or Head and Neck Cancer
• Polyphenon E in Treating Patients With High-Risk of Colorectal Cancer
• Dose Finding Study of Once or Twice Weekly IMMU-130 in Metastatic Colorectal Cancer
• Yoga and Bolus Lukewarm Saline as Rapid Colonoscopy Preparation
• Combined Anticancer Treatment of Advanced Colon Cancer
• A Study of Neoadjuvant Photodynamic Immunomodulation for Colon Cancer
• Randomized Phase II Adjuvant Chemotherapy ± FANG™ in Colorectal Carcinoma With Liver Metastases
• Combining Curcumin With FOLFOX Chemotherapy in Patients With Inoperable Colorectal Cancer
• Phase 2 Study of Thermodox as Adjuvant Therapy With Thermal Ablation (RFA) in Treatment of Metastatic Colorectal Cancer(mCRC)
• An Observational Study of Adjuvant Treatment With Capecitabine (Xeloda) in Combination With Oxaliplatin in Participants With Stage III Colon Cancer
• Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)
• CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
• Sorafenib Tosylate, Bevacizumab, Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil in Treating Patients With Metastatic Colorectal Cancer
• Linifanib in Treating Patients With Advanced, Refractory Colorectal Cancer
• Complete Neoadjuvant Treatment for REctal Cancer (CONTRE)
• An Open Dose-finding Study of Oral Applied Hexaminolevulinate (HAL) Imaging in Patients With Suspicion or High Risk of Neoplasia in the Colon
• Improving the Immune System With Human IL-7 Vaccine in Older Subjects Who Have Had Chemotherapy
• A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
• Combination Chemotherapy and Bevacizumab Before Surgery and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer
• Adjuvant Therapy(3 vs. 6 Months) With the FOLFOX 4 or XELOX for Stage II or Stage III Colon Cancer
• Study of AUY922 and Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer
• Study of Skin Toxicity of Cetuximab: Find a Link Between Skin Inflammation and Tumor Response
• AZD6244 With Cetuximab for Solid Tumors and Colorectal Cancer
• Effect of Celecoxib on Perioperative Inflammatory Response in Colon Cancer
• Combination Chemotherapy and Bevacizumab With or Without RO4929097 in Treating Patients With Metastatic Colorectal Cancer
• Lenalidomide and Cetuximab in Treating Patients With Advanced Colorectal Cancer or Head and Neck Cancer
• Study to Assess the Tolerability, Safety and Efficacy of an Adapted Gut Cleansing Solution in Routine Colon Cleansing Prior to Colonoscopies
• Panobinostat and Fluorouracil Followed By Leucovorin Calcium in Treating Patients With Stage IV Colorectal Cancer Who Did Not Respond to Previous Fluorouracil-Based Chemotherapy
• Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
• Selumetinib and Cetuximab in Treating Patients With Refractory Solid Tumors
• Ridaforolimus With Cetuximab: Adv Non-Small Cell Lung, Colorectal, Head & Neck Cancer
• Radiolabeled Monoclonal Antibody Therapy, Combination Chemotherapy, and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• Phase I Study of Cetuximab With RO4929097 in Metastatic Colorectal Cancer
• Miralax (PEG 3350) vs. Golytely as Bowel Preparation for Screening Colonoscopy
• A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.
• Standard Therapy With or Without Surgery and Mitomycin C in Treating Patients With Advanced Limited Peritoneal Dissemination of Colon Cancer
• RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Celecoxib in Treating Patients With Stage III Colon Cancer Previously Treated With Surgery
• Study of JI-101 in Patients With Advanced Low Grade Endocrine Tumors, Ovarian Cancers or K-RAS Mutant Colon Cancers
• Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
• Lenalidomide and Cetuximab in Treating Patients With Metastatic Colorectal Cancer
• RO4929097 in Treating Patients With Metastatic Colorectal Cancer
• Clinical and Translational Study of STA-9090
• Neoadjuvant Treatment of Colon Cancer
• Azacitidine and Entinostat in Treating Patients With Metastatic Colorectal Cancer
• Study of Micrometastases in Patients With Stage I or Stage II Localized Colon Cancer That Can Be Removed by Surgery
• Study Investigating the Role of Oxaliplatin Duration in Modified FOLFOX-6 or CAPOX Regimen as Adjuvant Colon Cancer Therapy
• Safety of BKM120 Monotherapy in Advanced Solid Tumor Patients
• Study of Perifosine + Capecitabine for Colon Cancer Patients
• Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
• Study of Pazopanib and Ixabepilone in Patients With Solid Tumors
• Rosuvastatin in Treating Patients With Stage I or Stage II Colon Cancer That Was Removed By Surgery
• Preoperative Chemosensitivity Testing to Predict Treatment Benefit in Adjuvant Stage III Colon Cancer
• Dose-Escalation Study in Advanced Colon Cancer Patients
• Thromboprophylaxis for Patients Undergoing Surgical Resection for Colon Cancer
• Combination Chemotherapy for 3 Months or 6 Months in Treating Patients With Stage III Colon Cancer
• Vorinostat, Fluorouracil, and Leucovorin Calcium in Treating Patients With Metastatic Colorectal Cancer That Has Not Responded to Previous Treatment
• Cediranib Maleate and Whole Brain Radiation Therapy in Patients With Brain Metastases From Non-Small Cell Lung Cancer
• Drug-Eluting Bead, Irinotecan (DEBIRI) Therapy of Liver Metastasis From Colon Cancer With Systemic Fluorouracil, Oxaliplatin, Leucovorin and Bevacizumab
• A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies
• Dipeptide Alanyl Glutamine and Postoperative Insulin Resistance in Colon Carcinoma Patients
• Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery
• Outpatient Health Care Program for Older Patients Receiving Chemotherapy for Newly Diagnosed Breast Cancer or Colon Cancer
• Exploratory Study Of The ERCC-1 Gene
• A Study of Irinotecan and Cetuximab With or Without IMC-A12 for Treatment of Participants With Colon or Rectum Cancer Who Got Worse After Their First Treatment With Oxaliplatin and Bevacizumab
• Cetuximab and/or Dasatinib in Patients With Colorectal Cancer and Liver Metastases That Can Be Removed by Surgery
• Eniluracil Hand Foot Syndrome
• Neoadjuvant FOLFOX Plus Bevacizumab Chemotherapy in Patients With Locally Advanced Colon Cancer
• Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer
• PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors
• Safe, Effective, and More Tolerable 16 Tablets Colon Prep
• A Safety Study of Pentamidine in Patients With Metastatic Colon Cancer Undergoing Standard Chemotherapy as Second-line and/or Third-line Treatment
• Panitumumab Combination Study With Rilotumumab or Ganitumab in Wild-type Kirsten Rat Sarcoma Virus Oncogene Homolog (KRAS) Metastatic Colorectal Cancer (mCRC)
• Yttrium Microspheres With Cetuximab Plus Irinotecan for Patients With Advanced Colorectal Cancer Mets to Liver
• BLI850 vs an Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
• BLI850-302: BLI850 vs an Approved Active Control Bowel Preparation in Adult Subjects Undergoing Colonoscopy
• Erlotinib Hydrochloride in Treating Patients With Stage I-III Colorectal Cancer or Adenoma
• A Phase 2, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma
• Efficacy of Morning-only Bowel Preparation for Afternoon Colonoscopy.
• Regional Anesthesia in Colon Rectal Surgery
• NGR-hTNF Administered in Combination With a Standard Oxaliplatin Based Regimen in Patients With Metastatic Colorectal Cancer
• Mangafodipir as an Adjunct to FOLFOX6 Chemotherapy in Colon Cancer Stage Dukes' C
• Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery
• Fluorouracil and Oxaliplatin With or Without Panitumumab In Treating Patients With High-Risk Colon Cancer That Can Be Removed by Surgery
• FOLFOX-4 3months Versus 6 Months and Bevacizumab as Adjuvant Therapy for Patients With Stage II/III Colon Cancer
• Hepatic Arterial Infusion of Floxuridine, Gemcitabine Hydrochloride, and Radiolabeled Monoclonal Antibody Therapy in Treating Liver Metastases in Patients With Metastatic Colorectal Cancer Previously Treated With Surgery
• Phase 1b/2 Study of AMG 655 With mFOLFOX6 and Bevacizumab for First-Line Metastatic Colorectal Cancer
• Phase II Trial of Abraxane and Capecitabine in Metastatic Colon Cancer (COL 01)
• A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
• OBELIX Study: A Study of Avastin (Bevacizumab) in Combination With XELOX in Patients With Metastatic Cancer of the Colon or Rectum.
• Veliparib and Irinotecan Hydrochloride in Treating Patients With Cancer That Is Metastatic or Cannot Be Removed by Surgery
• Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
• First-Line Bevacizumab and Chemotherapy in Metastatic Cancer of the Colon or Rectum - International Study
• Concentration of Ertapenem in Colorectal Tissue
• Dasatinib in Treating Patients With Previously Treated Metastatic Colorectal Cancer
• A Study of Xeloda (Capecitabine) as Adjuvant Monotherapy in Patients With Colon Cancer.
• Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic Colorectal Cancer That Progressed During First-Line Therapy
• A Study of the Perioperative Use of Cetuximab in Colon Cancer Patients
• Safety Study of Recombinant NAPc2 to Prevent Tumor Progression and Metastases in Metastatic Colon Cancer
• Resveratrol in Treating Patients With Colorectal Cancer That Can Be Removed By Surgery
• Fluorouracil, Semustine, and Vincristine Compared With BCG in Treating Patients With Dukes' B or Dukes' C Colon Cancer That Has Been Removed By Surgery
• Effect of Postoperative Laxative on Bowel Function After Colonic Surgery
• Liver Infusions of Fluorouracil in Treating Patients With Dukes' A, Dukes' B, or Dukes' C Colon Cancer Undergoing Surgery
• Comparison of 2L NRL994 With NaP Preparation in Colon Cleansing Prior to Colonoscopies for Colon Tumor Screening
• Fluorouracil and Leucovorin and/or Levamisole After Surgery In Treating Patients With Dukes' B Or Dukes' C Colon Cancer
• VEGF Trap in Treating Patients With Previously Treated Metastatic Colorectal Cancer
• AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer
• A Study of Palifermin for the Reduction of Oral Mucositis in Subjects With Stage 2B or 3 Locally Advanced, Colon Cancer
• A Study of ZYC300 Administered With Cyclophosphamide Pre-Dosing
• Combination Chemotherapy in Treating Patients With Resected Colon Cancer
• Irinotecan and Cetuximab for Colorectal Cancer as Second Line Therapy
• Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy
• Combination Chemotherapy and Bevacizumab in Treating Patients With Stage IV Colon Cancer That Cannot Be Removed By Surgery
• Randomized Trial on Adjuvant Chemotherapy in Colon Carcinoma Dukes B
• Randomized Study on Adjuvant Chemotherapy and Adjuvant Chemo-Immunotherapy in Colon Carcinoma Dukes C
• Phase III Trial of Gemcitabine, Curcumin and Celebrex in Patients With Metastatic Colon Cancer
• IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
• Gemcitabine and Oxaliplatin as Second-Line Therapy in Treating Patients With Metastatic Colon Cancer
• MOSAIC - Multicenter International Study of Oxaliplatin/ 5FU-LV in the Adjuvant Treatment of Colon Cancer
• Combination Chemotherapy With or Without Cetuximab in Treating Patients With Stage III Colon Cancer That Was Completely Removed By Surgery
• MASCOT : Multicenter Asia Study in Adjuvant Treatment of Colon Cancer With OxaliplaTin/5FU-LV
• GM-CSF and Combination Chemotherapy in Treating Patients Who Are Undergoing Surgery for Stage II or Stage III Colon Cancer
• Cellular Immune Augmentation in Colon and Rectal Cancer
• Resveratrol for Patients With Colon Cancer
• A Study of MLN8054 in Patients With Advanced Solid Tumors
• Clinical Trial in Patients With Metastatic Colorectal Cancer
• Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
• Prospective Phase II Randomized Trial of Postoperative Adjuvant Chemotherapy in Patients With High Risk Colon Cancer
• Study Evaluating Isovorin in Colon Cancer
• Bevacizumab and Cetuximab in Combination With FOLFOX6 in Patients With Metastatic Colorectal Cancer
• Enzastaurin for Patients With Metastatic Colorectal Cancer
• Imaging Colo-rectal Cancer Using a Two Step Antibody Technique in Nuclear Imaging
• Study of Xeloda and Gleevec in Patients With Advanced Solid Tumors
• MEK Inhibitor PD-325901 To Treat Advanced Breast Cancer, Colon Cancer, And Melanoma.
• Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors
• Sorafenib, Cetuximab, and Irinotecan in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Thymidylate Synthase Polymorphisms as a Predictor of Toxicity to 5-Fluorouracil Based Chemotherapy in Stage III Colon Cancer
• Trial for Microarray Analysis of Colon Cancer Outcome-A (MACCO-A)
• Combination Chemotherapy With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for High Risk Stage II or Stage III Colon Cancer
• SB-715992 in Treating Patients With Advanced or Metastatic Colorectal Cancer
• Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer
• Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
• Fluorouracil, Leucovorin, and Oxaliplatin With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II or Stage III Colon Cancer
• Chemotherapy Administered Every 2 Weeks With or Without Pegfilgrastim in Subjects With Advanced or Metastatic Colon Cancer
• Fluorouracil and Irinotecan With or Without Leucovorin Compared With Observation in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
• Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
• Vaccine Therapy and Sargramostim With or Without Docetaxel in Treating Patients With Metastatic Lung Cancer or Metastatic Colorectal Cancer
• Celecoxib in Preventing Polyps in Patients Who Have Undergone Surgery for Stage I Colon Cancer
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung Cancer
• GTI-2040, Oxaliplatin, and Capecitabine in Treating Patients With Locally Advanced or Metastatic Colorectal Cancer or Other Solid Tumors
• Clinical Trial in Patients With Metastatic Colorectal Cancer
• Comparison of Combination Chemotherapy Regimens With or Without Cetuximab in Treating Patients Who Have Undergone Surgery For Stage III Colon Cancer
• Bevacizumab and Cetuximab With or Without Irinotecan in Treating Patients With Irinotecan-Refractory Metastatic Colorectal Cancer
• Study Evaluating EKB-569 in Advanced Colorectal Cancer
• Neoadjuvant and Adjuvant Capecitabine and Oxaliplatin in Treating Patients With Resectable Liver Metastases Secondary to Colorectal Cancer
• Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer
• A Study of Xeloda (Capecitabine) Plus Oxaliplatin in Patients With Colon Cancer
• Study Evaluating MAC-321 in Colorectal Cancer
• A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Metastatic Colorectal Cancer.
• Study of Oxaliplatin/5-FU/Leucovorin Plus Vatalanib Versus Oxaliplatin/5-FU/Leucovorin in Patients With Previously Treated Metastatic Colorectal Cancer
• Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Colon Cancer
• Safety Study of hMN14 to Treat Either Colorectal or Breast Cancer
• Imatinib Mesylate in Treating Patients With Stage IV Colorectal Cancer
• Safety Study of 90Y-hMN14 to Treat Colorectal Cancer
• EPO906 Therapy in Patients With Advanced Colorectal Cancer
• Erlotinib in Treating Patients With Recurrent or Metastatic Colorectal Cancer
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)
• Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction
• Hepatic Arterial Infusion Plus Chemotherapy in Treating Patients With Colorectal Cancer Metastatic to the Liver
• Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
• Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
• Vaccine Therapy in Treating Patients With Metastatic Cancer
• Isolated Hepatic Perfusion With Melphalan Followed By Chemotherapy in Treating Patients With Unresectable Colorectal Cancer That is Metastatic to the Liver
• Vaccine Therapy in Treating Patients With Colon, Pancreatic, or Lung Cancer
• Vaccine Therapy in Treating Patients With Stage II or Stage III Colon Cancer That Has Been Removed During Surgery
• A Study of Xeloda (Capecitabine) Compared With 5-Fluorouracil in Combination With Low-Dose Leucovorin in Patients Who Have Undergone Surgery for Colon Cancer
• Combination Chemotherapy With or Without Irinotecan in Treating Patients With Stage III Colon Cancer
• SU5416 and Irinotecan in Treating Patients With Advanced Colorectal Cancer
• Celecoxib to Prevent Colorectal Cancer in Patients Who Have Undergone Surgery to Remove Polyps
• Irinotecan Compared With Combination Chemotherapy in Treating Patients With Advanced Colorectal Cancer
• Fluorouracil Plus Leucovorin With or Without Oxaliplatin in Treating Patients With Stage II or Stage III Colon Cancer
• Treatment of Peritoneal Cancer With Surgery, Perfused Heated Cisplatin and Chemotherapy
• High-Dose Fluorouracil With or Without Leucovorin Compared With Standard Fluorouracil Plus Leucovorin Following Surgery in Treating Patients With Stage III Colon Cancer
• Fluorouracil With or Without Eniluracil in Treating Patients With Advanced Colorectal Cancer
• Combination Chemotherapy in Treating Patients With Stage III Colon Cancer
• Antineoplaston Therapy in Treating Patients With Colon Cancer
• Antineoplaston Therapy in Treating Patients With Metastatic or Unresectable Colon Cancer
• Radiation Therapy Plus Irinotecan in Treating Patients With Colon Cancer
• Phase I-II Study of Fluorouracil in Combination With Phenylbutyrate in Advanced Colorectal Cancer
• S9415 Chemotherapy in Patients With Stage II or III Colon Cancer That Has Been Surgically Removed
• Perioperative Chemotherapy in Treating Patients With Colon Cancer That Can Be Surgically Removed
• A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab
• Women's Health Initiative (WHI)